Bioventus Q2 Earnings Call Highlights
· finance.yahoo.com
Bioventus (NASDAQ:BVS) reported second-quarter 2026 revenue growth of 4% and reiterated its full-year financial outlook, citing double-digit expansion in its Pain Treatments business, continued debt reduction and increased investment in platelet-rich plasma, peripheral nerve stimulation, Ultrasonics
Adjusted earnings were $0.22 per diluted share, compared with $0.21 a year earlier. Chief Financial Officer Mark Singleton said adjusted net income rose to $20 ...